目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。
这些人随机给培美曲塞或安慰剂，并持续21天的周期。
现就培美曲塞治疗晚期大肠癌的临床研究进展作一综述。
根据研究，药物的毒性作用使5%的培美曲塞组和4%的安慰剂组停药。
培美曲塞二钠及其右旋对映体的保留时间分别为8.7和。
培美曲塞联合铂类制剂治疗恶性胸膜间皮瘤的有效性与安全性
1·The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
2·Pemetrexed disodium is the only agent for the treatment of malignant pleural mesothelioma(MPM).
培美曲塞二钠是唯一治疗恶性胸膜间皮瘤（ MPM）的药物。
3·Pemetrexed is a multitargeted antimetabolite that has shown activity in malignant pleural mesothelioma and NSCLC, which has been approved in more than 70 countries.
培美曲塞是一种多靶点的抗代谢类药物，目前已经在70余个国家批准上市，用于治疗恶性胸膜间皮瘤和非小细胞肺癌。
4·Pemetrexed is a multi-target anti-folate agents, by inhibiting the activity of enzymes which are necessary for folic acid synthesis to inhibit DNA replication and thus inhibit the tumor growth.
培美曲塞是一种多靶点抗叶酸制剂，通过抑制合成叶酸所必需的酶的活性来抑制DNA的复制从而抑制肿瘤生长。
5·As the current evidence shows, pemetrexed has similar efficacy to docetaxel for advanced NSCLC patients, but it has fewer side effects of neutropenia, febrile neutropenia and alopecia.
结论当前证据显示，培美曲塞与多西紫杉醇治疗晚期NSCLC的疗效相当，但可减少中性粒细胞减少、粒细胞性发热和脱发等不良反应。